No products in the cart.
Niche Marketing
Able to rival J&J, Takeda’s development plan bears fruit with FDA nod for area of interest lung most cancers drug Exkivity
16
Sep
Sep
Takeda has been hoping its Wave 1 pipeline of medicines can drive near-term growth, but the group has been through a rough patch lately. With an FDA go-ahead for a niche lung cancer drug, the Japanese pharma has finally scored a regulatory win and has its chance to challenge Johnson & Johnson. The FDA granted […]